CYNTHIA SHAUGHNESSY: Open Payments
NPI 1063060374 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$493 in 19 payments from 14 companies in 2025. Trend: 2023 $662 · 2024 $630 · 2025 $493
Food & beverage: $488Education: $6
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 2 | $147 |
| Vifor Pharma, Inc. | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $63 |
| GENZYME CORPORATION | 1 | $32 |
| Vantive US Healthcare LLC | 1 | $29 |
| Veloxis Pharmaceuticals, Inc. | 1 | $27 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| AKEBIA THERAPEUTICS INC | 1 | $18 |
| Amgen Inc. | 1 | $18 |
Products named: TARPEYO, Veltassa, VOYXACT, FABRAZYME, Renal - PD, JYNARQUE, ENVARSUS, Vanrafia.
Industry payments across MO — which companies pay providers there.
